Jia Jenny Liu, Translational Lead of Early Phase Drug Development at The Kinghorn Cancer Centre, shared a post on LinkedIn:
A few reflections from the Omico.
Australian Precision Oncology Symposium (APOS26) today.
Precision oncology has made extraordinary progress in identifying actionable alterations. Australia is punching above its weight in driving precision oncology trials including ASPIRATION, LUMOS and MOST-PANCREAS.
But one message came through clearly across multiple talks:
Generating molecular data is no longer the main bottleneck.
Several presentations showed how comprehensive genomic profiling can identify additional actionable alterations beyond standard testing and increase uptake of targeted therapies.
But three challenges kept resurfacing:
1. Biology is more complex than genomics alone.
As therapies increasingly target proteins, particularly with the rise of ADCs and other targeted biologics the field will likely need to integrate proteomics and functional biology alongside genomics.
2. Interpretation is becoming the limiting step.
We can generate vast amounts of molecular data, but translating that into clear treatment decisions for individual patients remains difficult.
3. Access is the real gap. Sustainable funding required for biomarkers especially in the era of Хэштег#tumouragnostic immunotherapy approvals.
Even when actionable alterations are identified, patients still need a pathway to the right therapy or clinical trial.
Precision oncology is entering a new phase that is moving beyond sequencing alone toward integrated molecular profiling and smarter therapeutic, genetic counselling and clinical trial navigation.
Great to see colleagues from Omico, Garvan, UNSW, ProCan Technologies, Peter MacCallum and across the Australian precision oncology community driving this conversation.”
Other articles about Precision Oncology on OncoDaily.
